目前国内免疫药物主要有PD-1单抗和PD-L1单抗两大类。大家可能觉得，这两种药物其实是针对同一免疫通路的两个端点，机制上似乎是一致的。其实不然，两者之间存在着一定的区别，无论是在药物设计、作用机制到临床疗效，甚至耐药处理上都有不同之处。今天就全面给 ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

See now: Merck says trial of combination treatment for colon cancer failed to meet main goal PD-L1 is found in healthy cells ...

Radiopharm Theranostics has received approval from the Australian Ethics Committee for the inclusion of more tumour types ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

New research shows white blood cells activated by COVID-19 may have cancer-fighting abilities, offering hope for future ...

Junshi Biosciences' Loqtorzi has received MHRA approval for NPC and ESCC, marking the first NPC drug and a PD-L1-independent ...

which is indicated for use alongside PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel in adult patients with metastatic non ...

Merck’s phase 3 trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints: Rahway, New Jersey Thursday, November 21, 2024, 10:00 Hrs [IST] Merck, k ...

Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...